Samsung Biologics disclosed on the 20th that it will acquire 100% of PolyPeptide Group for 1.46 billion Swiss francs (approximately 2.7 trillion Korean won), the largest pharmaceutical merger and acquisition in Korean industry history. The acquisition expands Samsung Biologics' contract development and manufacturing organization (CDMO) services from antibody drugs, mRNA, and antibody-drug conjugates into the peptide sector, targeting surging demand for GLP-1 obesity and diabetes treatments. Despite the strategic announcement, Samsung Biologics' stock price fell 1.93% in early trading to 1.369 million won due to investor concerns over the large cash outlay and profit-taking after recent gains.
Samsung Biologics Announces 2.7 Trillion Won PolyPeptide Group Acquisition
Samsung Biologics announced via regulatory filing on the 20th that it has signed a contract to acquire 100% equity of PolyPeptide Group for 1.46 billion Swiss francs. The transaction structure includes purchasing the 55.65% controlling stake and launching a tender offer for all remaining shares excluding treasury stock. Samsung Biologics will establish a local subsidiary to conduct an all-cash tender offer at 44.31 Swiss francs per share. The expected transfer date is November 30, with final completion scheduled for the end of December.
Stock Price Falls 1.93% in Early Trading
At 9:33 AM on the 20th, Samsung Biologics traded at 1.369 million won, down 1.93% from the previous session. The stock opened at 1.428 million won but turned lower in early trading. Market analysts attributed the decline to concerns over the short-term financial burden from the massive cash investment and profit-taking following recent stock price gains.
Acquisition Expands Service Portfolio into Peptide CDMO
Samsung Biologics will expand its service business from antibody drugs, mRNA (messenger ribonucleic acid), and ADC (antibody-drug conjugates) into the peptide sector through this acquisition. Peptides are short chains of amino acids that primarily function as signaling molecules in the body. When artificially synthesized, they become peptide drugs — GLP-1 (glucagon-like peptide-1) obesity and diabetes treatments serve as a key example. Global pharmaceutical companies are expanding peptide pipelines beyond obesity and diabetes into anticancer drugs, immune disorders, and brain disease treatments. Samsung Biologics made the acquisition decision to address production demand for obesity drugs and other peptide medicines. The company will also inherit all ongoing CDMO contracts performed by PolyPeptide Group and plans to review production facility expansion as the peptide market grows to meet customer demand in a timely manner. According to global investment banks, the global obesity treatment market is projected to reach up to $150 billion (approximately 200 trillion won) by 2035.
PolyPeptide Group Background and Capabilities
PolyPeptide Group was spun off in 1996 from the peptide business division of global pharmaceutical company Ferring and is recognized as a major player in the global peptide CDMO market. The company has accumulated over 1,000 development and production records for peptide therapeutics and is evaluated as possessing industry-leading peptide substance production process development capabilities. PolyPeptide Group has also secured eco-friendly manufacturing technology that reduces organic solvent usage. The company's strategic value has been highlighted as demand for peptide drugs centered on obesity and diabetes treatments has grown in recent years.
Executive Statements on Strategic Combination
John Rim, CEO of Samsung Biologics, stated, "This acquisition is a strategic decision encompassing all three growth pillars — production capacity, business portfolio, and global footprint — and will contribute to enhancing corporate value and shareholder value. The two companies will combine their unparalleled capabilities to provide customers with broader and superior solutions and strengthen competitiveness in the global CDMO market."
Peter Wilden, Chairman of the Board of Directors at PolyPeptide Group, said, "The combination of Samsung Biologics' production capabilities and operational know-how will not only provide customers with more differentiated services but also secure a solid competitive advantage in the global peptide CDMO market."
FAQ
What did Samsung Biologics announce on the 20th?
Samsung Biologics announced on the 20th via regulatory filing that it will acquire 100% of PolyPeptide Group for 1.46 billion Swiss francs (approximately 2.7 trillion Korean won), marking the largest merger and acquisition in Korean pharmaceutical and biotechnology industry history.
Why did Samsung Biologics' stock price fall despite the acquisition announcement?
Samsung Biologics' stock price fell 1.93% in early trading to 1.369 million won due to investor concerns over the short-term financial burden from the large cash outlay and profit-taking after recent stock price gains.
How does the PolyPeptide Group acquisition expand Samsung Biologics' business?
The acquisition expands Samsung Biologics' CDMO services from antibody drugs, mRNA, and antibody-drug conjugates into the peptide sector, enabling the company to address production demand for GLP-1 obesity and diabetes treatments and other peptide medicines as global pharmaceutical companies expand peptide pipelines.
